Biotechnology and Pharmaceuticals: Hims & Hers Takes Advantage of Novo Nordisk Patent Lapse in Canada
Wednesday, 9 July 2025, 13:01
Biotechnology's Impact on Pharmaceuticals in Canada
In a groundbreaking move, Hims & Hers is set to offer generic semaglutide in Canada as the patent of Novo Nordisk A/S lapses. This comes after the company failed to pay a crucial maintenance fee in 2019, allowing competitors to enter the market.
Market Dynamics Shift in the Health Care Industry
- With Novo Nordisk A/S's patents on Ozempic and Wegovy expiring, we can anticipate an influx of affordable options for weight management.
- Eli Lilly and Co. will undoubtedly be monitoring these shifts closely, as they have their own competitive stakes in the market.
New Opportunities in Pharmaceuticals
This development not only highlights the power of biotechnology in reshuffling the business landscape, but it also emphasizes the potential for increased accessibility within the health care industry.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.